GSK completes acquisition of Nuvalent for $10.6 billion

GSK plc announced on July 15, 2026 that it had completed its acquisition of Nuvalent, Inc., a Boston-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies.¹

The transaction was structured as a tender offer to acquire all of Nuvalent's outstanding shares.¹ Financially, the aggregate equity value of the transaction is approximately $10.6 billion (£8.0 billion).¹ Net of cash acquired, GSK's aggregate investment is approximately $9.4 billion (£7.1 billion).¹

The acquisition brings three lung cancer programs into GSK's portfolio. It adds three lung cancer assets to GSK's oncology portfolio, including zidesamtinib (NVL-520) and neladalkib (NVL-655), which are under FDA review for ROS1-positive and ALK-altered non-small cell lung cancer (NSCLC) with target decision dates later this year.¹ Both compounds have regulatory designations: both have received FDA Breakthrough Therapy and Orphan Drug Designations.¹ GSK said if approved, they are expected to launch in 2026 with multi-blockbuster potential.¹

The deal also includes an earlier-stage program: the acquisition also includes NVL-330 in phase I development for HER2-altered NSCLC.¹

CEO Luke Miels said the deal accelerates our entry into lung cancer with zidesamtinib and neladalkib and a platform for rapid expansion with Ris-Rez, our B7-H3 targeted ADC in phase III development.¹

GSK noted that the original agreement to acquire Nuvalent was announced in a GSK press release issued 9 June titled "GSK enters agreement to acquire Nuvalent, Inc."¹